
PCSK9 inhibitors regress plaque without the calcification surge seen with statins
Explains the 'statin paradox' (statins reduce events and plaque but raise coronary calcium as plaque densifies) and argues PCSK9 inhibitors regress plaque without a calcific surge. Cites GLAGOV (evolocumab, LDL 36.6 mg/dL, PAV -0.95% vs +0.05%), PACMAN-AMI (alirocumab triple regression) and Gao 2022 (CAC +2.9% vs +10.6%).
